Cencora Q2 revenue and adjusted EPS miss estimates, raises FY outlook

أمريسورس برجين

Cencora, Inc.

COR

0.00


Overview

  • Pharmaceutical distributor's fiscal Q2 revenue rose 3.8% yr/yr but missed analyst expectations

  • Adjusted EPS for fiscal Q2 rose 7.5% but missed analyst expectations

  • Company raised full-year adjusted EPS guidance and plans $1 bln share buyback by end-2026


Outlook

  • Cencora raises fiscal 2026 adj diluted EPS guidance to $17.65-$17.90

  • Company expects fiscal 2026 revenue growth of 4%-6%

  • Cencora plans to repurchase $1 bln in shares by end of calendar 2026


Result Drivers

  • SEGMENT GROWTH - Revenue growth driven by 2.9% increase in U.S. Healthcare Solutions and 13.0% increase in International Healthcare Solutions, mainly due to higher unit volumes and growth in European distribution

  • ONEONCOLOGY ACQUISITION - Gross profit margin improvement and higher operating expenses attributed to the February 2026 acquisition of OneOncology

  • LOWER MARGIN PRODUCT MIX - Higher sales of GLP-1 products, which have lower gross profit margins, partially offset gross profit margin gains


Company press release: ID:nBw41ZmYba


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$78.36 bln

$81.09 bln (10 Analysts)

Q2 Adjusted EPS

Miss

$4.75

$4.81 (12 Analysts)

Q2 EPS

$8.40

Q2 Net Income

$1.63 bln

Q2 Adjusted Operating Income

Slight Miss*

$1.30 bln

$1.31 bln (9 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Cencora Inc is $400.00, about 30.8% above its May 5 closing price of $305.90

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 20 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


ترجمة هذه الصفحة آلية. تحاول منصة سهم تحسين الترجمة ولكن لا تضمن دقتها وموثوقيتها، ولن تتحمل المسؤولية عن أي خسارة أو ضرر بسبب عدم دقة أو إغفال في الترجمة. *المخاطر وإخلاء المسؤولية: يمثل المحتوى أعلاه المسؤولية الشخصية للمؤلف وآرائه فقط، ولا يمثل أي مسؤولية لمنصة سهم، ولا يمكن لمنصة سهم تأكيد صحة ودقة ومصداقية المحتوى أعلاه. يجب على المستثمرين مراعاة مخاطر المنتجات الاستثمارية على ضوء ظروفهم الخاصة قبل اتخاذ أي قرارات استثمارية. عند الضرورة، يرجى استشارة مستشار استثمار محترف. لا تقدم منصة سهم أي مشورة استثمارية، ولا تقدم أي التزامات أو ضمانات.